Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 28, 2017

DrugPatentWatch Database Preview

Neostigmine methylsulfate - Generic Drug Details

« Back to Dashboard

What are the generic sources for neostigmine methylsulfate and what is the scope of freedom to operate?

Neostigmine methylsulfate
is the generic ingredient in two branded drugs marketed by Fresenius Kabi Usa, Eurohlth Intl Sarl, and Eclat Pharms Llc, and is included in three NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for neostigmine methylsulfate. Five suppliers are listed for this compound.

Summary for Generic Name: neostigmine methylsulfate

Tradenames:2
Patents:1
Applicants:3
NDAs:3
Drug Master File Entries: see list6
Suppliers / Packagers: see list5
Bulk Api Vendors: see list51
Clinical Trials: see list66
Patent Applications: see list606
Therapeutic Class:Antimyasthenic Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:neostigmine methylsulfate at DailyMed

Pharmacology for Ingredient: neostigmine methylsulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS203629-001Jan 8, 2015RXNoNo► Subscribe► Subscribe
Eurohlth Intl Sarl
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS207042-001Dec 28, 2015APRXNoNo► Subscribe► Subscribe
Eurohlth Intl Sarl
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS207042-002Dec 28, 2015APRXNoNo► Subscribe► Subscribe
Eclat Pharms Llc
BLOXIVERZ
neostigmine methylsulfate
SOLUTION;INTRAVENOUS204078-002May 31, 2013APRXYesYes► Subscribe► Subscribe
Eclat Pharms Llc
BLOXIVERZ
neostigmine methylsulfate
SOLUTION;INTRAVENOUS204078-001May 31, 2013APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Formulary management

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot